IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, has scheduled its 2024 full year financial and operational results announcement for March 27, 2025. The company will release its results before the Nasdaq market opens, followed by a conference call at 10:00 AM EDT.

The conference call will be accessible via US dial-in (1-888-407-2553) and International dial-in (+972-3-918-0696). A live webcast will be available, with a recording subsequently posted on the company's investor relations website.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, ICCM declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAESAREA, Israel, March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day.

Conference call & webcast info:
Thursday, March 27, 2025, at 10:00 am EDT
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at:  https://Veidan.activetrail.biz/IcecureQ4-2024.
A recording of the webcast will be available at: ir.icecure-medical.com/.

About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

IR Contact: 

Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914

Todd Kehrli
Phone: 310-625-4462

Logo - https://mma.prnewswire.com/media/2319310/4496307/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-2024-full-year-financial--operational-results-on-march-27-2025-302407150.html

SOURCE IceCure Medical

FAQ

When will IceCure Medical (ICCM) release its 2024 full year financial results?

IceCure Medical will release its 2024 full year results before Nasdaq market opens on March 27, 2025.

How can investors join IceCure Medical's (ICCM) Q4 2024 earnings call?

Investors can join via US dial-in (1-888-407-2553), International dial-in (+972-3-918-0696), or watch the live webcast at 10:00 AM EDT on March 27, 2025.

Where can I find the replay of IceCure Medical's (ICCM) 2024 earnings webcast?

The webcast recording will be available on IceCure Medical's investor relations website at ir.icecure-medical.com

What time is IceCure Medical's (ICCM) Q4 2024 earnings conference call?

The conference call is scheduled for 10:00 AM EDT on March 27, 2025.